A Study to Examine the Effect of Pramlintide on Body Weight and its Safety and Tolerability in Obese Subjects
Study identifier:137OB-201
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and its Safety and Tolerability in Obese Subjects
Medical condition
obesity
Phase
Phase 2
Healthy volunteers
No
Study drug
pramlintide acetate
Sex
All
Actual Enrollment
400
Study type
Interventional
Age
18 Years - 70 Years
Date
Study Start Date: 01 May 2005
Primary Completion Date: 01 Nov 2005
Study Completion Date: 01 Nov 2005
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Apr 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
N/A
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Pramlintide Acetate | - |
| Placebo Comparator: Placebo | - |
Contacts
Contact
AstraZeneca Clinical Study Information Center Clinical Study Information Center
Investigators
Principal Investigator
Lisa Porter
Amylin Pharmaceuticals
